Dasiglucagon acetate

Dasiglucagon (CAS No.: 1544300-84-6) is a stabilized peptide analog of human glucagon and is categorized as an endocrine metabolic research reagent within peptide hormone signaling studies, developed to model glucagon receptor biology through increased resistance to degradation relative to native glucagon and to support reproducible interrogation of glucoregulatory mechanisms in biomedical research and drug discovery workflows; biologically, it functions as an agonist of the glucagon receptor GCGR, a class B G protein coupled receptor predominantly linked to Gs mediated activation of adenylate cyclase, elevation of intracellular cyclic AMP, and downstream protein kinase A dependent signaling that promotes hepatic glycogenolysis and gluconeogenic transcriptional programs in experimental systems, with additional pathway level investigation often extending to cAMP response element binding networks and broader metabolic stress signaling contexts; published descriptions consistently indicate robust receptor activating potency in cell based assays at low exposure levels that are generally characterized in the nanomolar to low micromolar range depending on assay format, receptor expression, and endpoint selection, while exact concentration response parameters should be confirmed under laboratory specific conditions; in practice, this molecule is commonly used in hepatocyte like cell models, engineered GCGR reporter platforms, and rodent metabolism studies to benchmark glucagon axis modulation, profile pathway selective responses, and evaluate comparator compounds in screening cascades focused on metabolic target validation, and the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, with all use restricted to controlled research settings and not intended for human consumption or non research applications.